Cancer
- About the area
- Groups
The area of cancer research has been structured into three different pillars: clinical research, translational laboratory research and innovation in cancer diagnosis and treatment.
Within the clinic, we can currently find four lines of research that have to do with the volume of incidence and prevalence of neoplastic disease, such as: breast cancer, lung cancer, urological tumors and gastrointestinal tumors. Each of them is made up of professionals who are dedicated to the diagnosis, treatment and follow-up of specific neoplasms.
In all lines there is extensive experience in conducting national and international studies. Many of the members belong to different national and international scientific societies, which allows them to be in touch with the latest scientific advances. Work is currently underway to increase the specific number of clinical research lines.
Within translational research, the goal has been set in the study at the cellular and molecular level of cancer with particular interest in the identification of new biomarkers that allow us to predict the survival of our cancer patients in their different types and stages, as well as adapting the treatment in a more personalized way. Work is also underway to increase cooperation with all those professionals who are researching into some type of cancer.
Finally, the cancer innovation group is investigating several strategic lines for the development of new diagnostic and treatment tools using new technologies with potential application in health.
Strategic lines of the area
- Research into new oncological therapies.
- Study of biomarkers involved in the prognosis and prediction of the effectiveness of oncological treatments.
- Search for new diagnostic tools based on artificial intelligence.
Group A1G4 - Biomedical research in cancer
Accreditation level: Consolidated group
The incidence of cancer is gradually increasing worldwide, as well as being one of the leading causes of death in our environment. The importance of having new knowledge about the behavior of the disease is a challenge of obvious relevance.
The Biomedical Research in Cancer group is a group with a long clinical research history. It is made up of professionals from different medical and surgical specialties, which allows us to tackle cancer research in a multidisciplinary and global way, addressing the prognostic, clinical and molecular factors of cancer, as well as developing new treatment options. Specifically, the group is working on the study of new drugs and therapies for breast, ovarian, head and neck, lung, digestive, and thyroid cancers.
The group participates with national and international companies and groups, such as SEOM, GEICAM, SOGUG, TTD, GEMCAD and EORTC, which allows the development of projects in a wide field with which results are achieved with a high degree of evidence.
Lines of research
- Research into new drugs and effective therapies in cancer patients.
- Study of biomarkers involved in the prognosis and prediction of treatment efficacy.
- Search for supportive treatment for cancer patients: palliative care and improvement of treatment side effects.
- Oncogeriatric assessment tools. Definition and evaluation of its effectiveness and its impact on patients' quality of life.
Composition of the group
Enrique Gallardo Diaz (Cap de grup)
Elsa Dalmau Pórtulas (co-cap de grup)
Doctoral research staff
- Bejarano González, Natalia
- Castañer González, Eva
- Fernández Morales, Luís Antonio
- Garcia Borobia, Francisco Javier
- Garcia Monforte, Neus
- Guirao Garriga, Francisco Javier
- Querol Niñerola, Rosa
- Seguí Palmer, Miquel Àngel
- Medarde Ferrer, Meritxell
- Muñoz Rodríguez, Jesús
Predoctoral
- Domínguez García, Arturo
- García Rojo, Dario
- Hannaoui Hadi, Naim
Non-doctoral research staff
- Aparicio Rodríguez, Oscar
- Bonfill Abella, Teresa
- Llort Pursals, Gemma
- Medina Argení, Sandra
- Nogales Herranz, Sara
- Ribera Fernandez, Paula
- Ribot Luna, Laia
- Vila Martínez, Laia
- Yébenes Marsal, Mireia
Associated professionals
- Andreu Magarolas, Marta
- Barcons Vilaplana, Santi
- Cabrera Romero, José Manuel
- Gallardo Cistaré, Xavier
- Giner Joaquin, Júlia
- López Mestres, Aida
- Malet Munté, Antoni
- Nogueiras Pérez, Rosa
- Pérez Riverola, Víctor
- Prenafeta Moreno, Mario
- Puig Domingo, Jordi
- Ribot Berenguer, Teresa
Group A1G5 - Molecular and Translational Research in Cancer
Accreditation level: Popup group
The Molecular and Translational Research Group on Cancer carries out several projects aimed at research at the cellular and molecular level of cancer with particular interest in the search for biomarkers for the diagnosis, prognosis and prediction of response to treatment.
The aim is that the results of this research can be transferred to clinical practice and be able to offer cancer patients a more personalized and appropriate treatment for each type of tumor.
The group is made up of postdoctoral and predoctoral researchers, mostly from the pathology department of our Hospital. It also has close internal and external collaborations with researchers from various prestigious groups, which allows a multidisciplinary approach to research projects.
Lines of research
- Clinicopathological and molecular characterization of thyroid cancer.
- Research into new biomarkers for the diagnosis and prognosis of colon cancer.
- Research in the genomics of lung cancer.
- Clinicopathological and molecular characterization of endometrial and ovarian carcinoma.
Composition of the group
M. Rosa Bella Cueto (Cap de grup) | ORCID
Adrià Asensi Puig (co-cap de grup) | ORCID
Doctoral research staff
- Costa Trachsel, Irmgard
- Ferreres Piñas John Carlos
Predoctoral
- Arrieta Legorburu, Álex
- Onieva Carbajo, Ricard
- Papaleo, Natalia
Non-doctoral research staff
- Aguirre Neira, Fabiana Inés
- Blazquez Maña, Carmen María
- Escoda Giralt, Maria Rosa
- Nuez Zaragoza, Elisa
- Parra Parente, Tamara
- Reques Llanos, Armando
Associated professionals
- Carreras Salas, Ruben
- Sáez Artacho, Empar
Group A1G6 – Innovation in Neuro-Oncology
Accreditation level: Popup group
The innovation group in neuro-oncology is made up of different lines of basic and translational research whose general objectives are to improve current diagnostic tests to make them more reliable and personalized, as well as to investigate new potential treatments that are less invasive than the current ones in neurooncology
We aim for all the innovative results obtained to reach the healthcare sector in the shortest possible time, due to the positive impact this would have on patients. For this reason, our research team regularly participates in training programs for the acceleration and transfer of results, which provide us with knowledge about patentability and technological transfer of our solutions.
Specifically, our research focuses on:
- Use innovative cellular (3D) models that allow us to obtain more accurate results than conventional models, while reducing animal experimentation.
- Develop new potentially curative treatments based on state-of-the-art technologies that allow therapies to become more precise and personalized.
- Improve current brain tumor diagnosis techniques using: i) artificial intelligence (AI) in medical imaging techniques, and ii) liquid biopsy in order to identify tumor markers in peripheral blood.
- Predict and optimize the effects of radio-oncological treatments using Monte Carlo simulations.
Our multidisciplinary group is made up of scientific and clinical professionals from different areas in neuro-oncology (neurology, neurosurgery, neuroradiology). In addition, we collaborate with other I3PT groups as well as with other prestigious external groups (ALBA, ICN2, IBB-UAB, Eurecat, CST) which allows us to create the necessary synergies to continue innovating in the area of neuro-oncology .
Lines of research
- Investigation of the role of technological innovation in both the diagnosis and treatment of neoplasms in diagnostic support (IA) and in new non-pharmacological treatments.
- Exploration of more realistic (and comparable to neoplasm) cell cultures, which take into account cell-cell and cell-microenvironment interactions.
- Study of local magnetic hyperthermia for the treatment of resistant tumors. Optimization of magnetic nanoparticles.
- Preclinical study of the effects of adjuvant radiotherapy as a local dose enhancer.
- Clinical investigation of genetic markers of metastatic brain tumors.
Composition of the group
Silvia Gil Duran (Group leader)
Doctoral research staff
- Gil Duran, Sílvia
Non-doctoral research staff
- Abad Inchaurrondo, Itziar
- Alvarez Bonillo, Paula
- Andres Sanz, Julio A.
- Cardona Gallego, Eva
- Estela Herrero, Jordi
- Giner Joaquin, Julia
- Lorite Diaz, Nadia
- Martín Olóriz, Amaya
- Muiños Vázquez, Olalla
Associated professionals
- Codina Aroztegui, Clara
- Escribano Alcántara, Fernanda
- Martin Miramon, Joan Carles
- Tortajada Giménez, Lidia
- Villajos Fernández, María Teresa